EA201201192A1 - Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций - Google Patents

Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций

Info

Publication number
EA201201192A1
EA201201192A1 EA201201192A EA201201192A EA201201192A1 EA 201201192 A1 EA201201192 A1 EA 201201192A1 EA 201201192 A EA201201192 A EA 201201192A EA 201201192 A EA201201192 A EA 201201192A EA 201201192 A1 EA201201192 A1 EA 201201192A1
Authority
EA
Eurasian Patent Office
Prior art keywords
thienopyrimidines
pharmaceutical compositions
alkyl group
group intended
substitute alkyl
Prior art date
Application number
EA201201192A
Other languages
English (en)
Inventor
Армин Хеккель
Франк Химмельсбах
Йорг Клей
Торстен Леманн-Линтц
Норберт Редеманн
Ахим Зауэр
Лео Томас
Дитер Виденмайер
Филлип Блэк
Уэсли Блэкейби
Айан Линни
Маттиас Аустен
Джон Данилевич
Мартин Шнайдер
Кай Шрайтер
Original Assignee
Бёрингер Ингельхайм Интернациональ Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43970925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201201192(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Бёрингер Ингельхайм Интернациональ Гмбх filed Critical Бёрингер Ингельхайм Интернациональ Гмбх
Publication of EA201201192A1 publication Critical patent/EA201201192A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В заявке описаны новые тиенопиримидины общей формулыфармацевтические композиции, содержащие эти соединения, и их применение в терапии для профилактики и/или лечения заболеваний, на которые можно воздействовать путем ингибирования активности киназы Mnk1 и/или Mnk2 (Mnk2a или Mnk2b), и/или их вариантов.
EA201201192A 2010-02-26 2011-02-25 Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций EA201201192A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10154930 2010-02-26
PCT/EP2011/052813 WO2011104340A1 (en) 2010-02-26 2011-02-25 Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions

Publications (1)

Publication Number Publication Date
EA201201192A1 true EA201201192A1 (ru) 2013-04-30

Family

ID=43970925

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201201192A EA201201192A1 (ru) 2010-02-26 2011-02-25 Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций

Country Status (17)

Country Link
US (1) US8853193B2 (ru)
EP (1) EP2539343B1 (ru)
JP (1) JP5575275B2 (ru)
KR (1) KR20120131171A (ru)
CN (1) CN102858783A (ru)
AR (1) AR080328A1 (ru)
AU (1) AU2011219764A1 (ru)
BR (1) BR112012021453A2 (ru)
CA (1) CA2791114A1 (ru)
CL (1) CL2012002319A1 (ru)
EA (1) EA201201192A1 (ru)
ES (1) ES2562959T3 (ru)
IL (1) IL221164A0 (ru)
MX (1) MX2012009851A (ru)
TW (1) TW201141483A (ru)
UY (1) UY33245A (ru)
WO (1) WO2011104340A1 (ru)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8633201B2 (en) 2006-04-07 2014-01-21 Boehringer Ingelheim International Gmbh Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
KR20110045019A (ko) 2008-08-26 2011-05-03 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물을 위한 티에노피리미딘
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
EA201201192A1 (ru) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций
US8754079B2 (en) * 2010-02-26 2014-06-17 Boehringer Ingelheim International Gmbh Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
RU2012140961A (ru) 2010-02-26 2014-04-10 Джапан Тобакко Инк. ПРОИЗВОДНОЕ 1,3,4,8-ТЕТРАГИДРО-2Н-ПИРИДО[1,2-a]ПИРАЗИНА И ЕГО ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНИБИТОРА ИНТЕГРАЗЫ ВИЧ
CA2873975A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Thienopyrimidines
CA2873967A1 (en) 2012-05-21 2013-11-28 Bayer Pharma Aktiengesellschaft Substituted benzothienopyrimidines
JP6280546B2 (ja) 2012-06-26 2018-02-14 デル マー ファーマシューティカルズ ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
TW201412740A (zh) 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
EP2917185B1 (en) 2012-11-09 2017-05-10 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
US9556181B2 (en) 2013-02-01 2017-01-31 Bayer Pharma Aktiengesellschaft Substituted pyrazolopyrimidinylamino-indazoles
JP2016514087A (ja) 2013-02-01 2016-05-19 バイエル・ファルマ・アクティエンゲゼルシャフト 置換チエノピリミジンおよびその薬学的使用
US9675612B2 (en) 2013-03-06 2017-06-13 Bayer Pharma Aktiengesellschaft Substituted thiazolopyrimidines
JP2016519684A (ja) 2013-04-08 2016-07-07 デニス エム ブラウン 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物
EP3013805B1 (en) * 2013-06-28 2018-02-21 Evotec International GmbH Sulfoximine substituted quinazolines and their use as mnk1 and/or mnk2 kinase inhibitors
WO2015004024A1 (en) * 2013-07-08 2015-01-15 Bayer Pharma Aktiengesellschaft Substituted pyrazolo-pyridinamines
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
EP3077383B1 (en) 2013-12-04 2018-08-22 Evotec International GmbH Sulfoximine substituted quinazolines for pharmaceutical compositions
WO2015091156A1 (en) 2013-12-17 2015-06-25 Boehringer Ingelheim International Gmbh Sulfoximine substituted pyrrolotriazines for pharmaceutical compositions
WO2015169677A1 (en) * 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Sulfoximine substituted quinazolines for pharmaceutical compositions
GB201520500D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
GB201520499D0 (en) 2015-11-20 2016-01-06 Medical Res Council Technology Compounds
US20190117657A1 (en) * 2016-03-31 2019-04-25 South Australian Health And Medical Research Institute Limited Method of inhibiting high fat diet-related conditions
WO2019023651A2 (en) * 2017-07-28 2019-01-31 Massachusetts Institute Of Technology MODULATORS OF THE SMALL MOLECULE ANDROGEN RECEPTOR
WO2020139701A1 (en) * 2018-12-28 2020-07-02 Kronos Bio, Inc. Compounds, compositions, and methods for modulating androgen receptor activity
CN115667212A (zh) * 2020-05-29 2023-01-31 富士胶片富山化学株式会社 高纯度的n-(5-甲氧基-2-苯氧基苯基)甲磺酰胺及其制造方法
KR20230072373A (ko) 2021-11-17 2023-05-24 중앙대학교 산학협력단 티에노피리미딘 유도체를 유효성분으로 함유하는 lrrk2 억제용 조성물

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH408945A (de) 1956-02-10 1966-03-15 Ciba Geigy Verfahren zur Herstellung von heterocyclischen Verbindungen
DE3036390A1 (de) 1980-09-26 1982-05-13 Troponwerke GmbH & Co KG, 5000 Köln Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen
DD248593A1 (de) 1985-01-11 1987-08-12 Univ Halle Wittenberg Verfahren zur herstellung von 4-basischsubstituierten thieno/2,3-d/pyrimidin-6-ylcarbonsaeureestern
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
BR9101256A (pt) 1990-03-30 1991-11-05 Dowelanco Composto,composicao fungicida,processo fungicida,composicao inseticida ou acaricida e processo inseticida ou acaricida
TW370529B (en) 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
ES2109796T3 (es) * 1994-05-03 1998-01-16 Ciba Geigy Ag Derivados de pirrolopirimidilo con efecto antiproliferante.
EP0729758A3 (en) 1995-03-02 1997-10-29 Pfizer Pyrazolopyrimidines and pyrrolopyrimidines to treat neuronal disorders and other diseases
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
CA2309690A1 (en) 1997-11-11 1999-05-20 Pfizer Products Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
US20030162795A1 (en) * 1998-10-22 2003-08-28 Pfizer Inc. Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
WO2000075145A1 (en) 1999-06-03 2000-12-14 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
US6643277B2 (en) 2000-06-29 2003-11-04 Harris Broadband Wireless Access, Inc. Frequency re-use for point to multipoint applications
JP2002020386A (ja) * 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
WO2002088138A1 (en) 2001-04-30 2002-11-07 Bayer Corporation Novel 4-amino-5,6-substituted thiopheno[2,3-d]pyrimidines
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
JP4518378B2 (ja) 2001-10-29 2010-08-04 ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング エネルギー恒常性および細胞小器官代謝の調節に関与するＭｎｋキナーゼ相同性タンパク質
WO2004037159A2 (en) 2002-10-23 2004-05-06 Obetherapy Biotechnology Compounds, compositions and methods for modulating fat metabolism
US20050012622A1 (en) 2003-05-19 2005-01-20 Sutton William R. Monitoring and control of sleep cycles
WO2004106339A2 (en) 2003-05-28 2004-12-09 Università Degli Studi Di Siena 4-SUBSTITUTED DERIVATIVES OF PYRAZOLO [3,4-d] PYRIMIDINE AND PYRROLO [2,3-d] PYRIMIDINE AND USES THEREOF
MXPA05013227A (es) 2003-06-20 2006-03-09 Celltech R&D Ltd Derivados de tienopiridona como inhibidores de cinasa.
JP4712702B2 (ja) 2003-07-24 2011-06-29 バイエル・シエリング・フアーマ・アクチエンゲゼルシヤフト 高増殖性疾患を処置するために有用な置換されたテトラヒドロベンゾチエノピリミジンアミン化合物
US7419978B2 (en) 2003-10-22 2008-09-02 Bristol-Myers Squibb Company Phenyl-aniline substituted bicyclic compounds useful as kinase inhibitors
DE10351436A1 (de) * 2003-11-04 2005-06-09 Merck Patent Gmbh Verwendung von Thienopyrimidinen
CA2551689A1 (en) * 2004-01-05 2005-07-28 Merz Pharma Gmbh & Co. Kgaa Memantine for the treatment of mild and mild-to-moderate alzheimer's disease
EP1724268A4 (en) 2004-02-20 2010-04-21 Kirin Pharma Kk COMPOUND HAVING TGF-BETA INHIBITING ACTIVITY AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
EP1731523A4 (en) * 2004-04-01 2009-08-12 Takeda Pharmaceutical THIAZOLOPYRIMIDINE DERIVATIVE
GB0412467D0 (en) * 2004-06-04 2004-07-07 Astrazeneca Ab Chemical compounds
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
EP1746099A1 (en) * 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
DK1856252T3 (en) 2005-03-08 2015-03-09 Boehringer Ingelheim Int Crystallographic structure of MNK-1 and MNK-2 proteins
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
ES2623221T3 (es) 2005-05-20 2017-07-10 Methylgene Inc Inhibidores de la señalización del receptor de VEGF y del receptor de HGF
AU2006261082B2 (en) * 2005-06-22 2012-04-19 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
US20070099877A1 (en) * 2005-11-02 2007-05-03 Cytovia, Inc. N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US20070213305A1 (en) 2005-11-02 2007-09-13 Cytovia, Inc. N-alkyl-N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
WO2007059905A2 (en) 2005-11-25 2007-05-31 Develogen Aktiengesellschaft Thienopyrimidines treating inflammatory diseases
ES2395386T3 (es) 2005-12-21 2013-02-12 Abbott Laboratories Compuestos antivirales
WO2007084815A2 (en) 2006-01-19 2007-07-26 Janssen Pharmaceutica, N.V. Substituted thienopyrimidine kinase inhibitors
US8633201B2 (en) * 2006-04-07 2014-01-21 Boehringer Ingelheim International Gmbh Thienopyrimidines having Mnk1/Mnk2 inhibiting activity for pharmaceutical compositions
CA2654358A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
EP1889847A1 (en) 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
JP2011504474A (ja) * 2007-11-22 2011-02-10 ベーリンガー インゲルハイム インテルナツィオナール ゲゼルシャフト ミット ベシュレンクテル ハフツング アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用
ES2893580T3 (es) * 2007-11-28 2022-02-09 Dana Farber Cancer Inst Inc Inhibidores de miristato de moléculas pequeñas de Bcr-abl y métodos de uso
WO2009093662A1 (ja) * 2008-01-25 2009-07-30 Sharp Kabushiki Kaisha 移動局装置及びプログラム
US20100015708A1 (en) * 2008-06-18 2010-01-21 Mdrna, Inc. Ribonucleic acids with non-standard bases and uses thereof
KR20110045019A (ko) * 2008-08-26 2011-05-03 베링거 인겔하임 인터내셔날 게엠베하 약제학적 조성물을 위한 티에노피리미딘
US20130065914A1 (en) * 2010-02-26 2013-03-14 Boehringer Ingelheim International Gmbh Halogen or cyano substituted thieno [2,3-d]pyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
US8754079B2 (en) * 2010-02-26 2014-06-17 Boehringer Ingelheim International Gmbh Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
EA201201192A1 (ru) 2010-02-26 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
ES2583015T3 (es) * 2011-09-07 2016-09-16 Nordex Energy Gmbh Procedimiento para la fabricación de un componente de pala de rotor de instalación de energía eólica con un larguero principal prefabricado

Also Published As

Publication number Publication date
JP2013520474A (ja) 2013-06-06
CL2012002319A1 (es) 2012-10-12
AR080328A1 (es) 2012-03-28
BR112012021453A2 (pt) 2017-02-21
AU2011219764A1 (en) 2012-08-16
ES2562959T3 (es) 2016-03-09
US8853193B2 (en) 2014-10-07
MX2012009851A (es) 2012-09-12
WO2011104340A1 (en) 2011-09-01
JP5575275B2 (ja) 2014-08-20
KR20120131171A (ko) 2012-12-04
US20110212103A1 (en) 2011-09-01
EP2539343B1 (en) 2015-12-30
CA2791114A1 (en) 2011-09-01
CN102858783A (zh) 2013-01-02
UY33245A (es) 2011-09-30
IL221164A0 (en) 2012-09-24
TW201141483A (en) 2011-12-01
EP2539343A1 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
EA201201192A1 (ru) Тиенопиримидины, содержащие замещенную алкильную группу, предназначенные для фармацевтических композиций
EA201201193A1 (ru) Тиенопиримидины, содержащие гетероциклоалкил, предназначенные для фармацевтических композиций
PH12017501306A1 (en) Inhibitors of histone demethylases
EA201201191A1 (ru) 4-[циклоалкилокси(гетеро)ариламино]тиено[2,3-d]пиримидины, обладающие ингибирующей активностью по отношению к mnkl/mnk2, предназначенные для фармацевтических композиций
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201391230A1 (ru) Соединения и композиции в качестве ингибиторов trk
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
IN2014DN09434A (ru)
EA201490891A1 (ru) Пиридопиразины, обладающие противораковой активностью через ингибирование fgfr киназ
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
MX2013007336A (es) Compuestos de bi-heteroarilo como inhibidores de vps34.
EA201391033A1 (ru) Ингибиторы bace-2 для лечения метаболических расстройств
MX341212B (es) Inhibidor de bromodominio de benzodiazepina.
EA201200174A1 (ru) Производные оксазина и их применение в качестве ингибиторов bace для лечения неврологических нарушений
MX2011011335A (es) Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina.
MA33939B1 (fr) 5-alcynyl-pyrimidines
EA201790599A1 (ru) Соединения и композиции в качестве ингибиторов киназ
EA201100138A1 (ru) 4-феноксиметилпиперидины в качестве модуляторов активности gpr119
EA201370166A1 (ru) Содержащие диарилацетиленгидразид ингибиторы тирозинкиназы
GEP20166474B (en) Pyrazolospiroketone derivatives for use as acetyl-coa carboxylase inhibitors
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
MX2012001134A (es) Composiciones y metodos para inhibicion de la via jak.